Other Contributors

About Us

The contributors to the Consumer Law & Policy blog are lawyers and law professors who practice, teach, or write about consumer law and policy. The blog is hosted by Public Citizen Litigation Group, but the views expressed here are solely those of the individual contributors (and don't necessarily reflect the views of institutions with which they are affiliated). To view the blog's policies, please click here.

« Criminal Background Checks For Job Applicants Seriously Flawed, Says NCLC Report | Main | Survey shows corporations losing enthusiasm for arbitration of commercial contract disputes »

Friday, May 04, 2012


Aliza Lewis

In both the cases the difference is lying upon the preemption. Since FDA approval is taken to be a preempted one in consideration to the related generic drug government is either supporting or discarding the facts. PLIVA policy will be helping if the state tort claims are being put into the act for covering up the warning claims as well as the defected claims.

The comments to this entry are closed.

Subscribe to CL&P

RSS/Atom Feed

To receive a daily email of Consumer Law & Policy content, enter your email address here:

Search CL&P Blog

Recent Posts

September 2022

Sun Mon Tue Wed Thu Fri Sat
        1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30